Retatrutide Side Effects — What You Need to Know

Retatrutide Side Effects — What You Need to Know Before You Start

So you have been hearing a lot about Retatrutide lately. And honestly, it is not hard to see why.

The research data coming out of Eli Lilly’s Phase 2 and Phase 3 trials has turned heads across the metabolic science community. Up to 24.2% body weight reduction in 48 weeks. Improvements in blood glucose. Shifts in lipid profiles. For a research peptide, those are remarkable numbers.

But here is the question that comes up every single time — and it is the right question to ask:

What are the side effects of Retatrutide?

Whether you are a research professional reviewing protocol safety data, or someone who has simply been reading about this compound and wants to understand it better, this guide covers everything currently documented in published research. No hype, no scaremongering — just a clear, honest breakdown of what the data actually shows.

What Is Retatrutide and Why Does It Matter?

Before diving into the side effects, it helps to understand what Retatrutide actually is and why its mechanism produces the reactions it does.

Retatrutide (LY3437943) is a triple receptor agonist peptide. It simultaneously activates three hormone receptors — GLP-1, GIP, and glucagon — which is what makes it different from anything else currently in the research space. Most comparable compounds target one or two of these pathways. Retatrutide targets all three at once.

That triple-receptor approach is exactly why the weight loss data is so impressive. It is also why understanding the side effect profile requires looking at all three pathways, not just one.

With that context in place, here is what the research shows.

Common Retatrutide Side Effects — What the Research Data Shows

The side effects documented in Retatrutide trials are largely consistent with those seen across the broader GLP-1 receptor agonist class. If you are familiar with Semaglutide or Tirzepatide research data, some of these will look familiar.

Gastrointestinal Side Effects

The most frequently reported side effects in Retatrutide trials are gastrointestinal in nature. These include:

• Nausea — the most commonly reported reaction, particularly at higher dose levels and during the dose escalation phase
• Vomiting — reported less frequently than nausea, typically associated with rapid dose increases
• Diarrhoea — noted across multiple dose cohorts, generally mild to moderate in severity
• Constipation — reported by a subset of participants, particularly in longer-duration trial arms
• Decreased appetite — technically a pharmacological effect rather than an adverse reaction, but worth noting as it can be significant
• Abdominal discomfort — generalised stomach cramping or bloating reported in some participants

In Phase 2 trial data, these gastrointestinal effects were most pronounced during the early weeks of dose escalation and tended to reduce in frequency and intensity as participants progressed through the protocol. This is consistent with what is observed across the GLP-1 agonist class generally.

Injection Site Reactions

Because Retatrutide is administered subcutaneously, localised injection site reactions are documented in the trial data. These include:

• Mild redness or erythema at the injection site
• Localised swelling or induration
• Tenderness or discomfort around the administration site

These reactions are generally mild, transient, and manageable through standard site rotation practices.

Fatigue and General Effects

Some participants in Retatrutide trials reported:

• Fatigue or tiredness — particularly during the initial dose escalation phase
• Dizziness — reported in a small proportion of participants
• Headache — noted across trial arms, most commonly in early protocol weeks

These effects were generally self-limiting and reduced as participants adjusted to the compound over time.

Less Common Retatrutide Side Effects

Beyond the frequently reported reactions, published trial data also documents a smaller number of less common side effects. These are worth being aware of, even though they were reported in a minority of participants.

Does Retatrutide Cause Hair Loss?

This question comes up regularly in online research communities, and it deserves a direct answer.

Hair loss — specifically telogen effluvium — has been reported in association with GLP-1 receptor agonist peptides, including Semaglutide. It is not a direct pharmacological effect of the drug itself. It is instead associated with rapid caloric deficit and significant body weight reduction.

In Retatrutide trial data, hair thinning has been noted in some participants. However, current evidence suggests this is more likely related to the nutritional changes accompanying significant weight loss than a direct effect of the peptide compound itself. This distinction matters for researchers designing protocol parameters.

Retatrutide and Heart Rate

One notable observation from Retatrutide trial data is a modest increase in resting heart rate. This is consistent with glucagon receptor activation — the third receptor in Retatrutide’s triple-agonist mechanism.

In published Phase 2 data, mean increases in heart rate of approximately 2–5 beats per minute were observed across dose cohorts. For research purposes, this is a relevant parameter to monitor across protocol cycles, particularly in studies involving cardiometabolic endpoints.

Retatrutide Side Effects — Liver and Pancreas

As with all GLP-1 class peptides, the potential for pancreatic and hepatic effects is a monitored area in Retatrutide research.

• Pancreatitis: Rare cases have been reported in the GLP-1 agonist class broadly. In Retatrutide’s Phase 2 data, pancreatitis was not identified as a significant safety signal, but it remains a parameter monitored in ongoing trials.
• Liver enzyme changes: Given Retatrutide’s investigated role in NAFLD research, liver enzyme parameters are tracked in trial data. Some participants showed transient changes in liver markers, though these were not associated with clinical liver injury in published data.

Retatrutide Long-Term Side Effects — What Does the Data Say So Far?

This is one of the most important questions for any serious researcher — and one of the most honest answers in the field right now is: long-term data is still emerging.

Retatrutide is a relatively new compound. The longest published trial data currently covers 48 weeks of exposure. That gives researchers a solid picture of short-to-medium-term safety, but the long-term profile — beyond one year of continuous exposure — is still being established through ongoing Phase 3 trials.

What the current data does confirm:

• The side effect profile is consistent with and comparable to the established GLP-1 agonist class
• Serious adverse events were rare in Phase 2 data
• The most common side effects — gastrointestinal reactions — tended to decrease in frequency over time
• No novel safety signals have emerged in published data to date that are not already associated with the broader class

This is encouraging, but it reinforces why Retatrutide remains a research compound. The full long-term safety picture requires the ongoing Phase 3 data to mature.

Retatrutide Side Effects vs Mounjaro and Semaglutide — How Does It Compare?

A natural question for researchers reviewing Retatrutide data is how its side effect profile compares to Tirzepatide (Mounjaro) and Semaglutide — two compounds with more established safety datasets.

The short answer: the side effect profile is broadly similar across all three, with some nuances.

The most notable difference is the heart rate signal, which is more pronounced in Retatrutide data — likely attributable to glucagon receptor activation, which is absent in both Semaglutide and Tirzepatide. This makes it a particularly interesting parameter to track in cardiometabolic research protocols.

Is Retatrutide Safe?

This is the question underneath all the others — and it deserves a clear, honest answer.

Based on published Phase 2 trial data, Retatrutide demonstrates a safety profile that is consistent with the established GLP-1 receptor agonist class. Serious adverse events were uncommon. The most frequently reported reactions were gastrointestinal and were generally mild to moderate in severity.

However, it is critical to state clearly: Retatrutide is not approved for human use by the MHRA or the FDA. It is a research compound currently in clinical trials. All safety data referenced in this post comes from controlled clinical research settings under professional supervision.

It is not a compound to be self-administered outside of a properly structured research environment.

What This Means for Researchers Sourcing Retatrutide in the UK

If you are a UK-based research professional evaluating Retatrutide for your protocol, understanding the side effect profile is just one part of good research design. Equally important is sourcing a product of verified purity, because impure or incorrectly prepared peptide compounds introduce variables that make clean research impossible — and add unnecessary risk to your protocol.

At WeightLossPeptides, every Retatrutide product we stock is supplied at ≥98% purity (HPLC verified) with a Certificate of Analysis available for download. We stock both the Retatrutide 20mg Pen and the Retatrutide 40mg Pen, with full reconstitution documentation and BAC Water available to order alongside.

If you are ready to source Retatrutide for your UK research protocol, view our full Retatrutide product range below.

Frequently Asked Questions — Retatrutide Side Effects

What are the most common side effects of Retatrutide? The most commonly reported side effects in published trial data are nausea, vomiting, diarrhoea, and decreased appetite. These are most pronounced during dose escalation and tend to reduce over time.

Does Retatrutide cause hair loss? Hair thinning has been reported in some trial participants. Current evidence suggests this is more likely associated with rapid weight loss and caloric deficit than a direct pharmacological effect of the compound itself.

Does Retatrutide affect heart rate? Yes. A modest increase in resting heart rate of approximately 2–5 beats per minute has been observed in Phase 2 trial data. This is attributed to glucagon receptor activation and is a monitored parameter in ongoing trials.

How do Retatrutide side effects compare to Mounjaro? The profiles are broadly similar. The main distinction is a more pronounced heart rate signal in Retatrutide data, attributable to its glucagon receptor component — which Tirzepatide does not activate.

Are Retatrutide’s long-term side effects known? Long-term data beyond 48 weeks is still emerging from ongoing Phase 3 trials. Current published data shows a consistent and manageable profile, but the full long-term picture is not yet complete.

Is Retatrutide safe to use? Retatrutide is not approved for human use. All published safety data comes from controlled clinical trials. It is a research compound and must not be self-administered outside of a structured research protocol.

The Bottom Line on Retatrutide Side Effects

Retatrutide’s side effect profile is well-documented, broadly consistent with the GLP-1 agonist class, and manageable within a properly designed research protocol. The gastrointestinal reactions are the most common. The heart rate signal is the most distinct. And the long-term data, while encouraging so far, is still maturing.

For UK researchers looking to work with this compound, sourcing verified, research-grade Retatrutide from a trusted UK supplier is the essential first step.

View our Retatrutide 20mg Pen and Retatrutide 40mg Pen product pages for full specifications, pricing, and COA documentation.

⚠️ This blog post is published for educational and research information purposes only. Retatrutide is not approved for human use by the MHRA or FDA. Nothing in this article constitutes medical advice. Always conduct research in compliance with applicable regulations and under appropriate professional supervision.